[Top] [All Lists]

[e-drug] UU-WHO summer course programme in Utrecht, the Netherlands

E-DRUG: UU-WHO summer course programme in Utrecht, the Netherlands

Dear E-Druggers,

This summer, the Division of Pharmacoepidemiology and Clinical Pharmacology at 
Utrecht University, the Netherlands (the WHO CC for Pharmaceutical Policy and 
Regulation), offers you again three challenging international summer courses:

6-10 July 2015 - Pharmacoepidemiology & Drug safety

13-17 July 2015 - Pharmaceutical Policy Analysis (in collaboration with WHO)

20-24 July 2015 - Pharmacoeconomics

More detailed information can be found below and on the summer school website 
All courses will cover the key issues in each field and focus on the most 
important research methods used. All course teachers have extensive expertise 
in their field.

A few scholarships are available for the Pharmaceutical Policy Analysis course. 
These scholarships include course fee, basic student housing as described on 
the summer school website and a small daily allowance to cover expenses for 
food and local transport. International travel is at the expense of the 
applicant or his/her institution. 

If you wish to apply for a scholarship, please do so before 20 April 2015 by 
sending an application letter including motivation plus CV to our course 
assistant Winnie de Bruijn
All applicants will be notified by 1 May 2015.

Supplementary, there is a cultural and social programme arranged for 
participants to make sure that they experience the best of Utrecht.

Please feel free  to share this information with others who might be interested 
to attend. We look forward to welcoming you or them in Utrecht this summer!

Warm wishes,

Aukje Mantel,
Managing Director WHO CC for Pharmaceutical Policy & Regulation

M7 Pharmaceutical Policy Analysis (13-17 July 2015)
Medicines are among the most regulated products in society. From the earliest 
pre-clinical stages onward, policy makers want to foster the development of 
safe, effective and affordable medicines for patients in need of 
pharmacotherapy. When a drug reaches the market, it is the beginning of a 
process of complex interactions between patients, prescribers, insurers, 
pharmaceutical companies and governments. Furthermore, the inequity in access 
to medicines is still a defining characteristic of the global pharmaceutical 
market place.

The aim of the course is to give students insight into current developments in 
pharmaceutical policy making as well to give a better understanding of the 
methods available for analysing the effects of policy interventions. As a 
collaborator on this course, the World Health Organization will provide faculty 
for several of the sessions.

You will experience an intensive programme covering the following topics: 
Pharmaceutical Policy Analysis issues and methods; current challenges in drug 
innovation; universal health coverage; regulatory issues and challenges; 
country profiles; policy and politics; synthesis, case studies & public health

Course directors: Prof. Dr. Bert Leufkens, Dr. Kees de Joncheere (World Health 
Organization) and Dr. Aukje Mantel.

M8 Pharmacoepidemiology & Drug Safety (6-10 July 2015)
With the prospect that innovative drug therapies will be introduced in the 
coming years, society demands new approaches and concepts for comparative 
risk/benefit evaluation. Assessment of safety and risk management of different 
drug therapies is done in the framework of observational epidemiological 
studies (proof of ‘safety’, proof of ‘effectiveness’). This is the logical next 
step after randomized clinical trials, which are designed to provide evidence 
of a drugs ‘efficacy’.

The course will cover key issues in pharmacoepidemiologic and drug safety 
research. Special topics include databases and molecular pharmacoepidemiology. 
Students will learn about the typical problems (e.g. confounding by indication, 
rare side effects) and approaches to deal with these problems in the practice 
of pharmacoepidemiology.

You will experience an intensive programme covering the following topics: Study 
Design and Methods; Confounding and other biases; Methods in drug safety 
research; Drug Safety and Risk Management; Overview of Pharmacoepidemiological 
databases; Molecular Pharmacoepidemiology; Drug utilization research; 
Synthesis, case studies & public health

Course directors: Prof. dr. O.H. Klungel and Prof. dr. T.P. van Staa

M14 Pharmacoeconomics (20-24 July 2015)
Today's society is confronted with ever increasing health care costs. One of 
the factors is the cost of drug innovations. Diseases waiting for therapeutic 
solutions are complicated and multifactorial in nature. As a result, drug 
innovation has become even more complex leading to high tech and therefore high 
cost solutions. The question arises, what is the added value of such high cost 
innovations and how can it be determined when both benefit and harm are 
considered. Health economics, and more specific pharmacoeconomics, aims to 
provide a neutral scientific approach to this challenge.

This course aims to provide a broad perspective of the field, including a 
variety of subjects from views of the different stakeholders to more in depth 
methodological approaches, illustrated with examples and exercises.

You will experience an intensive programme covering the following topics: 
Pharmacoeconomic techniques; Study designs and methods; Critical appraisal of 
pharmacoeconomic studies; The (im)possibilities of the use of HTA and 
pharmacoeconomics in regulatory decisions; The economics of personalized 

Course directors: Dr. A. Hovels, Dr. G.W.J. Frederix, Prof. dr. J.A.M. 

General information for all courses

Target groups
(Post)graduates and professionals within governments, NGOs, industry, 
universities with a basic knowledge public health/medicine who have an interest 
in the policy aspects of pharmaceuticals, pharmacoepidemiology and/or 

Fee and combinations
€950,- per course (including course materials + lunches + course dinner, 
excluding housing). Combination fee for two courses is €1500,- (excluding 
housing), combination fee for all three courses combined is €1950,- (excluding 

Deadline for application
1 June 2015, see 
 (information re summer school, course registration and housing)

More information
Course assistant: Winnie de Bruijn 

Aukje Mantel-Teeuwisse, PhD
Director School of Pharmacy, Utrecht University 
Managing director WHO Collaborating Centre for Pharmaceutical Policy and 

Division Pharmacoepidemiology & Clinical Pharmacology 
PO Box 80 082 | 3508 TB Utrecht
The Netherlands | Tel: +31 6 22736017 or +31 30 253 7324 (secretariat)
Visiting address:
David de Wied building | Universiteitsweg 99 | 3584 CG Utrecht | the Netherlands
"Mantel-Teeuwisse, A.K. (Aukje)" <A.K.Mantel@uu.nl>

<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] UU-WHO summer course programme in Utrecht, the Netherlands, Mantel-Teeuwisse, A.K. (Aukje) <=